Department of Biotechnology, Karunya Institute of Technology and Sciences, Karunya Nagar, Coimbatore, Tamilnadu, 641114, India.
Biotechnology, ETH Zurich, Hebelstrasse, 17, 4056, Basel, Switzerland.
Mol Cell Biochem. 2019 Oct;460(1-2):105-112. doi: 10.1007/s11010-019-03574-z. Epub 2019 Jul 12.
This study aimed to find out the molecular therapeutic effect of lipo-ATRA on tumour suppressor TIG3 and cell proliferative biomarker PPARγ in B (a) P-induced lung cancer model. In RT-PCR study, ATRA- and lipo-ATRA-treated mice samples showed relatively higher TIG3 expression and decreased PPARγ expression (Band density) than cancer control. Among treatments, lipo-ATRA showed vital effect than free ATRA by enhancing TIG3 and decreasing PPARγ. The qPCR results also showed significant (p ≤ 0.05) difference in both TIG3 and PPAR (RQ values of TIG3, lipo-ATRA 23.85 ± 1.29; free ATRA 10.43 ± 1.81 and for PPARγ, lipo-ATRA 4.707 ± 1.21; free ATRA 15.78 ± 2.34). From this, we conclude that liposomal ATRA formulation is most preferable for prolonged delivery of ATRA at targeted site to favour molecular action. It implies that the therapeutic effect of lipo-ATRA in lung cancer was exhibited by ameliorating the TIG3 expression and by suppressing the expression of PPARγ.
本研究旨在探讨脂肪酰基维甲酸（Lipo-ATRA）对肿瘤抑制因子 TIG3 和细胞增殖生物标志物 PPARγ 在苯并（a）芘（B（a）P）诱导的肺癌模型中的分子治疗作用。在 RT-PCR 研究中，与癌症对照组相比，ATRA 和 Lipo-ATRA 处理的小鼠样本显示出相对较高的 TIG3 表达和降低的 PPARγ 表达（条带密度）。在这些治疗中，Lipo-ATRA 通过增强 TIG3 和降低 PPARγ 比游离 ATRA 显示出更重要的作用。qPCR 结果还显示 TIG3 和 PPAR 均有显著差异（p≤0.05）（TIG3 的 RQ 值，Lipo-ATRA 为 23.85±1.29；游离 ATRA 为 10.43±1.81，对于 PPARγ，Lipo-ATRA 为 4.707±1.21；游离 ATRA 为 15.78±2.34）。由此我们得出结论，脂质体 ATRA 制剂最适合于在靶向部位延长 ATRA 的递送，以促进分子作用。这意味着 Lipo-ATRA 在肺癌中的治疗效果是通过改善 TIG3 的表达和抑制 PPARγ 的表达来实现的。
